|1.||Werz, Oliver: 17 articles (08/2015 - 08/2005)|
|2.||Sautebin, Lidia: 14 articles (09/2014 - 06/2003)|
|3.||Rossi, Antonietta: 11 articles (09/2014 - 06/2003)|
|4.||Cuzzocrea, Salvatore: 11 articles (01/2007 - 06/2003)|
|5.||Praticò, Domenico: 10 articles (11/2015 - 04/2008)|
|6.||Ghosh, Jagadananda: 9 articles (02/2015 - 01/2002)|
|7.||Steinhilber, Dieter: 9 articles (01/2015 - 08/2005)|
|8.||Allayee, Hooman: 9 articles (08/2012 - 07/2002)|
|9.||Wei, Er-Qing: 9 articles (01/2012 - 04/2006)|
|10.||Funk, Colin D: 9 articles (05/2010 - 07/2002)|
12/01/2006 - "The results suggest that RBx 7,796, a novel chemotype, is an orally efficacious inhibitor of 5-lipoxygenase enzyme that is effective against both neutrophilic and eosinophilic airway inflammation and shows potent inhibition with once daily administration."
10/01/2013 - "Together with other recent studies, our recent findings identify an important role for the enzyme 5-lipoxygenase and its products in the induction and resolution of adipose tissue inflammation. "
06/01/2003 - "In the present study, by comparing the responses in wild-type (WT) mice and mice lacking [knockout (KO)] the 5-lipoxygenase (5-LO), we investigated the role played by 5-LO in the development of acute inflammation. "
09/15/1999 - "Studies were undertaken to define the role of 5-lipoxygenase (5-LO) products and, in particular, of leukotriene (LT) B4 in the polymorphonuclear leukocyte (PMN) emigration process using a rabbit model of dermal inflammation. "
03/28/1997 - "In this study, we asked whether neutrophil recruitment into sites of inflammation can alter the subcellular compartmentation of 5-lipoxygenase. "
|2.||Asthma (Bronchial Asthma)
03/27/1996 - "Three months of 5-lipoxygenase inhibition produced a significant improvement in asthma control. "
01/01/2013 - "Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study."
03/01/2005 - "Few studies have investigated the role of polymorphisms in the ALOX5AP gene, encoding 5-lipoxygenase activating protein (FLAP), and asthma. "
01/01/1999 - "A recent observation that a polymorphism in the 5-Lipoxygenase gene is linked to less responsiveness to a leukotrien-antagonist shows that the future perspectives of genetic studies may lie also in revealing the chromosomal map of the best therapy for an individual patient with asthma. "
05/14/2014 - "Stewart ex Brandis galls in bronchial asthma possibly related to its ability to inhibit L-subtype Cav channel, mast cell stabilization, antioxidant, angiostatic and through inhibition of 5-lipoxygenase enzyme."
04/01/2006 - "In the present study, by comparing the responses in wild-type mice (5-LOWT) with those of mice lacking the 5-lipoxygenase (5-LOKO), we investigated the role played by this enzyme in the permeability and structure of small intestine TJs in an animal model of experimental colitis. "
06/01/2005 - "In the present study, by comparing the responses in wild-type mice (5-LOWT) and mice lacking the 5-lipoxygenase (5-LOKO), we investigated the role played by this enzyme in the development of experimental colitis. "
04/01/2006 - "5-lipoxygenase modulates the alteration of paracellular barrier function in mice ileum during experimental colitis."
06/01/2005 - "5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration."
06/01/1996 - "The effect of intracolonic administration of zileuton (a 5-lipoxygenase inhibitor) on colonic damage and eicosanoid local release was assessed in a rat model of colitis. "
03/01/1992 - "Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis."
05/01/2007 - "The anomalies in the 5-lipoxygenase pathway were accompanied as expected by more cells immunostaining for cytokine-inducible COX-2 (P = 0.004, n = 17), but this study also revealed a greater number of cells expressing COX-1 in the samples from the patients in the ulcerative colitis subgroup (P = 0.03, n = 9). "
03/01/1992 - "We examined the effects of an inhibitor of 5-lipoxygenase (A-64077) in 11 patients with mild to moderately active ulcerative colitis (UC). "
03/24/1990 - "Selective 5-lipoxygenase inhibition in ulcerative colitis."
04/01/1988 - "As 4-aminosalicylic acid has been claimed to be beneficial in the topical treatment of ulcerative colitis, it was tested whether this drug possesses any influence on the 5-lipoxygenase activity in human neutrophils in vitro or whether it acts as a radical scavenger. "
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
01/01/1996 - "The present study indicates that a selective and highly potent 5-lipoxygenase inhibitor was not effective in the topical treatment of chronic plaque psoriasis."
05/01/1990 - "Therefore the role of an in vitro 5-lipoxygenase inhibitor and its clinical use in psoriasis were evaluated with topical R 68 151 in a double-blind vehicle-controlled study. "
05/01/1990 - "A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor."
01/01/1986 - "The results of our study support the view that abnormal 5-lipoxygenase activity is present in psoriasis. "
01/01/1993 - "It is concluded that 5-lipoxygenase activation does not play a significant role in the pathology of psoriasis and therefore selective leukotriene biosynthesis inhibitors would have no significant role in the treatment of this disease."
|2.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|3.||Arachidonic Acid (Vitamin F)
|5.||Cyclooxygenase 2 (Cyclooxygenase-2)
|7.||Leukotriene Antagonists (Leukotriene Receptor Antagonists)
|8.||2,3,5- trimethyl- 6- (12- hydroxy- 5,10- dodecadiynyl)- 1,4- benzoquinone
|2.||Homologous Transplantation (Allograft)
|4.||Drug Therapy (Chemotherapy)